Archive by Author

BioBuzz: Rachel King of GlycoMimetics Among 12 Women Who Have Shaped the History of the BioHealth Capital Region

Rachel 2018-09-28 Glycomimetics retouch-2-2

The BioHealth Capital Region (BHCR) and its life science ecosystem have a rich and deep history of pioneering scientific innovation, research, development, and commercialization. The region’s history has been written by life science anchor companies, scientific research universities, government research organizations, rich startup culture, and serial entrepreneurs, all of whom have played critical roles in […]

Comments Off on BioBuzz: Rachel King of GlycoMimetics Among 12 Women Who Have Shaped the History of the BioHealth Capital Region Continue Reading →

MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies

MAXCYTE-New-Logo-2016-LARGE

Agreement enables Allogene, a pioneer in the development of AlloCAR T™ therapies for cancer, to utilize MaxCyte’s ExPERT™ platform in target candidates GAITHERSBURG, MD, and SOUTH SAN FRANCISCO, CA, March 24, 2020 – MaxCyte, Inc., a global cell-based therapies and life sciences company, and Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development […]

Comments Off on MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies Continue Reading →

BioSpace: Maryland Booms in the BioCapital Hotbed

biospace

As the BioCapital Hotbed continues to grow, the state of Maryland is seeing a boom in life sciences employment as multiple companies build out manufacturing facilities in the state. Last year, Kite Pharma, a subsidiary of Gilead Sciences, broke ground on their Frederick, Maryland facility that will significantly expand the company’s ability to manufacture a variety of CAR-T therapies, […]

BioBuzz: MaxCyte's Jim Brady Among Gene Editing Experts Who Gathered to Discuss Transformative Potential of CRISPR on Genomic Medicine

Brady_Maxcyte-1

Montgomery College’s Bioscience Education Center (BEC) is the place to be, to see and to hear from some of the brightest life science minds in BioHealth Capital Region (BHCR).  Home to the region’s most important biotech workforce development and training programs, including; Bio-Trac, the graduate/post-graduate level program offering hands-on laboratory training workshops for research scientists, BioTrain, the incumbent worker […]

Comments Off on BioBuzz: MaxCyte's Jim Brady Among Gene Editing Experts Who Gathered to Discuss Transformative Potential of CRISPR on Genomic Medicine Continue Reading →

Maryland Tech Council Expands to Frederick to Create Larger Footprint in State of Maryland

MTCjpg

– Forming Workforce Coalition in Frederick to address issues tied to attracting and retaining human capital – Coordinating with Universities at Shady Grove to establish its Montgomery County offices – Launched “We are Here” Campaign to Emphasize Reach and Impact Throughout the State FREDERICK, Md.–(BUSINESS WIRE)–The Maryland Tech Council (MTC) announced today it has expanded its offices to Frederick to broaden […]

Comments Off on Maryland Tech Council Expands to Frederick to Create Larger Footprint in State of Maryland Continue Reading →

Technical.ly Baltimore: University of Maryland BioPark-based Startup ARMR Systems Raises $750K

ARMR

The University of Maryland BioPark-based company moved to Baltimore in 2017. Now it’s looking to continue growing a team as it moves its device to market.      Two years ago, ARMR Systems moved to Baltimore to base development of a device to stop bleeding before a medic can arrive. Now the University of Maryland BioPark-based startup has new investment […]

Comments Off on Technical.ly Baltimore: University of Maryland BioPark-based Startup ARMR Systems Raises $750K Continue Reading →

Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China

logo-glyco

Rockville biotech GlycoMimetics Inc. has entered into a license agreement worth $189 million or more with a West Coast company. The deal gives cancer therapy biopharma Apollomics Inc. of Foster City, California exclusive rights to develop and commercialize GlycoMimetics’ blood cancer drug in greater China, which encompasses mainland China, Hong Kong, Taiwan and Macau, the […]

Comments Off on Washington Business Journal: Maryland Biotech Outlines Path for Blood Cancer Drug, Including in China Continue Reading →

Technical.ly Baltimore: MTC's Martin Rosendale, UM BioPark's James Hughes and Others Share Their Thoughts on Baltimore's Imagined Future

TechBmore2-1180x600

Imagined futures: Baltimore tech and biz leaders tell us what they envision for the next decade The year is winding down, which offers time to pause and look back at how we were moving, reading, hiring and exiting in 2019. But in this case, it’s not just about one year: The coming calendar turnover marks […]

Comments Off on Technical.ly Baltimore: MTC's Martin Rosendale, UM BioPark's James Hughes and Others Share Their Thoughts on Baltimore's Imagined Future Continue Reading →

MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update

Shruti A 2X2 Final Maxcyte Portrait Dec 2019 DSC_6560 Coyle Studios

– Shrut Abbato will lead development of new partnerships for the Company’s CARMA platform programs – Phase I trial of lead CARMA candidate MCY-M11 remains on-track with the dosing of the third cohort of patents underway and no dose-limitng toxicites or related serious adverse events observed Gaithersburg, Maryland – DECEMBER 19, 2019: MaxCyte, the global clinical-stage […]

Comments Off on MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Provides Clinical Trial Update Continue Reading →

Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair

MHeffernan_Headshot

Cambridge, MA, December 17, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH), today announced that Michael Heffernan has joined the Board of Directors as Chairman. “Indalo’s unique approach to treating fibrosis, combined with a highly […]

Comments Off on Indalo Therapeutics Appoints Healthcare Industry Veteran and Serial Entrepreneur Michael Heffernan as Board Chair Continue Reading →